Sanofi Wins EU Approval
Sanofi secures EU approval for Cenrifki as first disability-targeting medicine for secondary progressive multiple sclerosis without relapses
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.